MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Core Insights - MDxHealth reported preliminary revenues for Q4 and full year 2025, with Q4 revenues of approximately $30.5 million and full year revenues of $109 million, reflecting year-over-year growth of 23% and 21% respectively [2][5] - The company issued revenue guidance for 2026, projecting revenues between $137 million and $140 million, indicating a year-over-year growth of 26-28% [3][5] - MDxHealth amended earnout terms with Exact Sciences, deferring payments related to the GPS acquisition, with payments scheduled for 2026, 2027, and 2028 totaling $54.5 million [4] Financial Performance - For Q4 2025, MDxHealth billed 11,201 tissue-based units and 27,486 liquid-based units, showing year-over-year growth of (5%) and 128% respectively [2] - For the full year 2025, the company billed 49,180 tissue-based units and 71,920 liquid-based units, representing year-over-year growth of 18% and 57% respectively [2] - The cash balance at year-end 2025 was reported at $29.0 million [2] Strategic Outlook - The CEO expressed confidence in the company's growth strategy, emphasizing the strength of the sales channel and expanded offerings to the urology customer base [5] - The company anticipates achieving an adjusted EBITDA margin run rate of 10% by the end of 2026 [5]